Last 12 months
Inside the activity.
0 purchase rows · 26 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 6 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2018 Filed Mar 21, 2018 22:00 UTC |
Maag PeterDirector · See Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000899243-18-008270 · doc4.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2022-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 2/48ths of the shares subject to this option vested and became exercisable on the Date Exercisable set forth in column 6 and each month thereafter until October 1, 2013. 1/36th of the remaining shares vested and became exercisable each month thereafter. Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 22:00 UTC |
Maag PeterDirector · See Remarks
|
Exercise / conversionCommon Stock | 50,000 | $0.55 | $27,400.00 |
DisclosureSEC source: 0000899243-18-008270 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:37 UTC |
Maag PeterDirector · See Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 89,938 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000899243-18-004365 · doc4.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 89,938 shares Expires 2022-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 2/48ths of the shares subject to this option vested and became exercisable on the Date Exercisable set forth in column 6 and each month thereafter until October 1, 2013. 1/36th of the remaining shares vested and became exercisable each month thereafter. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:37 UTC |
Maag PeterDirector · See Remarks
|
Exercise / conversionCommon Stock | 89,938 | $0.55 | $49,286.02 |
DisclosureSEC source: 0000899243-18-004365 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 17:02 UTC |
Yee James PChief Medical Officer
|
Tax withholdingCommon Stock | 805 | $6.25 | $5,031.25 |
DisclosureSEC source: 0000899243-18-002275 · doc4.xml · nonDerivative · entry 1 Yee James P · CIK 0001421336 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,102 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 16:59 UTC |
Nelles Mitchell JChief Operating Officer
|
Tax withholdingCommon Stock | 805 | $6.25 | $5,031.25 |
DisclosureSEC source: 0000899243-18-002273 · doc4.xml · nonDerivative · entry 1 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,639 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 21:59 UTC |
Sninsky John JosephChief Scientific Officer
|
Tax withholdingCommon Stock | 805 | $6.25 | $5,031.25 |
DisclosureSEC source: 0000899243-18-002272 · doc4.xml · nonDerivative · entry 1 Sninsky John Joseph · CIK 0001630732 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,309 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 21:55 UTC |
Maag PeterDirector · See Remarks
|
Tax withholdingCommon Stock | 1,450 | $6.25 | $9,062.50 |
DisclosureSEC source: 0000899243-18-002269 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,099 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 18:51 UTC |
Nelles Mitchell JChief Operating Officer
|
Tax withholdingCommon Stock | 1,691 | $6.29 | $10,636.39 |
DisclosureSEC source: 0000899243-18-001706 · doc4.xml · nonDerivative · entry 1 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,586 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 18:52 UTC |
Yee James PChief Medical Officer
|
Tax withholdingCommon Stock | 1,691 | $6.29 | $10,636.39 |
DisclosureSEC source: 0000899243-18-001707 · doc4.xml · nonDerivative · entry 1 Yee James P · CIK 0001421336 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,907 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 23:49 UTC |
Sninsky John JosephChief Scientific Officer
|
Tax withholdingCommon Stock | 886 | $6.29 | $5,572.94 |
DisclosureSEC source: 0000899243-18-001705 · doc4.xml · nonDerivative · entry 1 Sninsky John Joseph · CIK 0001630732 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,114 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 23:47 UTC |
Maag PeterDirector · See Remarks
|
Tax withholdingCommon Stock | 3,726 | $6.29 | $23,436.54 |
DisclosureSEC source: 0000899243-18-001704 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,124 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 22, 2018 Filed Jan 25, 2018 19:46 UTC Amendment |
Nelles Mitchell JChief Operating Officer
|
Tax withholdingCommon Stock | 1,691 | $6.29 | $10,636.39 |
DisclosureSEC source: 0000899243-18-002029 · doc4a.xml · nonDerivative · entry 1 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,444 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. F2 · balance_after: This amendment is being filed solely to correct the number of non-derivative securities reported on the original Form 4 as beneficially owned by the Reporting Person as of January 22, 2018; 8,858 shares of the Issuer's common stock were inadvertently omitted. Read SEC document |
| January 22, 2018 Filed Jan 26, 2018 00:45 UTC Amendment |
Maag PeterDirector · See Remarks
|
Tax withholdingCommon Stock | 3,726 | $6.29 | $23,436.54 |
DisclosureSEC source: 0000899243-18-002028 · doc4a.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,549 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. F2 · balance_after: This amendment is being filed solely to correct the number of non-derivative securities reported on the original Form 4 as beneficially owned by the Reporting Person as of January 22, 2018; 44,425 shares of the Issuer's common stock were inadvertently omitted. Read SEC document |
| January 19, 2018 Filed Jan 25, 2018 19:41 UTC |
King SashaChief Commercial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-002023 · doc4.xml · derivative · entry 1 King Sasha · CIK 0001721150 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-19 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 25, 2018 19:43 UTC |
Karlsson AndersChief Commercial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 9,638 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-002026 · doc4.xml · derivative · entry 2 Karlsson Anders · CIK 0001672871 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,638 Underlying: Common Stock · 9,638 shares Expires 2028-01-19 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 25, 2018 19:43 UTC |
Karlsson AndersChief Commercial Officer
|
GrantCommon Stock | 9,638 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002026 · doc4.xml · nonDerivative · entry 1 Karlsson Anders · CIK 0001672871 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,638 F1 · shares: The reported securities are represented by restricted stock units 1/4th of which shall vest on January 19, 2019 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| January 19, 2018 Filed Jan 25, 2018 19:36 UTC |
Nelles Mitchell JChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 8,858 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-002015 · doc4.xml · derivative · entry 2 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,858 Underlying: Common Stock · 8,858 shares Expires 2028-01-19 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 25, 2018 19:36 UTC |
Nelles Mitchell JChief Operating Officer
|
GrantCommon Stock | 8,858 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002015 · doc4.xml · nonDerivative · entry 1 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,135 F1 · shares: The reported securities are represented by restricted stock units 1/4th of which shall vest on January 19, 2019 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| January 19, 2018 Filed Jan 25, 2018 19:40 UTC |
Yee James PChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-002022 · doc4.xml · derivative · entry 1 Yee James P · CIK 0001421336 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-19 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 26, 2018 00:39 UTC |
Bell Michael BrianChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 14,013 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-002020 · doc4.xml · derivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,013 Underlying: Common Stock · 14,013 shares Expires 2028-01-19 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 26, 2018 00:39 UTC |
Bell Michael BrianChief Financial Officer
|
GrantCommon Stock | 14,013 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002020 · doc4.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,738 F1 · shares: The reported securities are represented by restricted stock units 1/4th of which shall vest on January 19, 2019 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| January 19, 2018 Filed Jan 26, 2018 00:32 UTC |
Maag PeterDirector · See Remarks
|
GrantEmployee Stock Option (right to buy) · Derivative | 44,425 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-002010 · doc4.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,425 Underlying: Common Stock · 44,425 shares Expires 2028-01-19 F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 26, 2018 00:32 UTC |
Maag PeterDirector · See Remarks
|
GrantCommon Stock | 44,425 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002010 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,275 F1 · shares: The reported securities are represented by restricted stock units 1/4th of which shall vest on January 19, 2019 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| January 02, 2018 Filed Jan 2, 2018 20:54 UTC |
HAGSTROM WILLIAM ADirector
|
GrantCommon Stock | 1,844 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000158 · doc4.xml · nonDerivative · entry 1 HAGSTROM WILLIAM A · CIK 0001042875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,159 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2018 Filed Jan 2, 2018 20:52 UTC |
SNYDERMAN RALPHDirector
|
GrantCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000156 · doc4.xml · nonDerivative · entry 1 SNYDERMAN RALPH · CIK 0001178031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,578 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 01:53 UTC |
Goldberg MichaelDirector
|
GrantCommon Stock | 3,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000157 · doc4.xml · nonDerivative · entry 1 Goldberg Michael · CIK 0001366412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,865 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 01:51 UTC |
Bickerstaff GeorgeDirector
|
GrantCommon Stock | 2,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000155 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,786 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| December 08, 2017 Filed Dec 8, 2017 19:59 UTC |
Yee James PChief Medical Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,197 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0000899243-17-028300 · doc4.xml · derivative · entry 3 Yee James P · CIK 0001421336 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,197 shares Expires 2018-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option vested monthly over a four year period commencing January 1, 2008 and became fully vested on January 1, 2012. Read SEC document |
| December 08, 2017 Filed Dec 8, 2017 19:59 UTC |
Yee James PChief Medical Officer
|
SaleCommon Stock | 29,197 | $7.00 | $204,379.00 |
DisclosureSEC source: 0000899243-17-028300 · doc4.xml · nonDerivative · entry 2 Yee James P · CIK 0001421336 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,598 Read SEC document |
| December 08, 2017 Filed Dec 8, 2017 19:59 UTC |
Yee James PChief Medical Officer
|
Exercise / conversionCommon Stock | 29,197 | $3.36 | $97,999.73 |
DisclosureSEC source: 0000899243-17-028300 · doc4.xml · nonDerivative · entry 1 Yee James P · CIK 0001421336 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2017 Filed Nov 30, 2017 21:23 UTC |
Nelles Mitchell JChief Operating Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,948 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0000899243-17-027731 · doc4.xml · derivative · entry 3 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,948 shares Expires 2018-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested monthly over a four year period commencing January 1, 2008 and became fully vested on January 1, 2012. Read SEC document |
| November 30, 2017 Filed Nov 30, 2017 21:23 UTC |
Nelles Mitchell JChief Operating Officer
|
SaleCommon Stock | 10,948 | $7.17 | $78,487.31 |
DisclosureSEC source: 0000899243-17-027731 · doc4.xml · nonDerivative · entry 2 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,277 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.135 to $7.22, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| November 30, 2017 Filed Nov 30, 2017 21:23 UTC |
Nelles Mitchell JChief Operating Officer
|
Exercise / conversionCommon Stock | 10,948 | $3.36 | $36,785.28 |
DisclosureSEC source: 0000899243-17-027731 · doc4.xml · nonDerivative · entry 1 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 16:05 UTC |
SNYDERMAN RALPHDirector
|
GrantOption to Purchase Common Stock · Derivative | 6,679 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026011 · doc4.xml · derivative · entry 2 SNYDERMAN RALPH · CIK 0001178031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,679 Underlying: Common Stock · 6,679 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 16:05 UTC |
Nelles Mitchell JChief Operating Officer
|
GrantOption to Purchase Common Stock · Derivative | 8,906 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026010 · doc4.xml · derivative · entry 2 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,906 Underlying: Common Stock · 8,906 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 14,597 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 8,906 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 16:15 UTC |
Yee James PChief Medical Officer
|
GrantOption to Purchase Common Stock · Derivative | 13,359 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026023 · doc4.xml · derivative · entry 2 Yee James P · CIK 0001421336 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,359 Underlying: Common Stock · 13,359 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 21,897 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a stock option for 13,359 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:10 UTC |
Cohen Fred EDirector
|
GrantOption to Purchase Common Stock · Derivative | 6,679 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026018 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,679 Underlying: Common Stock · 6,679 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:08 UTC |
Goldberg MichaelDirector
|
GrantOption to Purchase Common Stock · Derivative | 37,453 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026016 · doc4.xml · derivative · entry 2 Goldberg Michael · CIK 0001366412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,453 Underlying: Common Stock · 37,453 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 61,386 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 37,453 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:08 UTC |
Maag PeterDirector · See Remarks
|
GrantOption to Purchase Common Stock · Derivative | 69,474 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026015 · doc4.xml · derivative · entry 2 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,474 Underlying: Common Stock · 69,474 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 113,868 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a stock option for 69,474 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:05 UTC |
Bickerstaff GeorgeDirector
|
GrantOption to Purchase Common Stock · Derivative | 6,679 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026009 · doc4.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,679 Underlying: Common Stock · 6,679 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 16:05 UTC |
SNYDERMAN RALPHDirector
|
Disposition to issuerOption to Purchase Common Stock · Derivative | 10,948 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026011 · doc4.xml · derivative · entry 1 SNYDERMAN RALPH · CIK 0001178031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,948 shares Expires 2024-06-19 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F1 · derivative.exercise_date: The shares underlying the cancelled option were vested and immediately exercisable. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 16:05 UTC |
Nelles Mitchell JChief Operating Officer
|
Disposition to issuerOption to Purchase Common Stock · Derivative | 14,597 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026010 · doc4.xml · derivative · entry 1 Nelles Mitchell J · CIK 0001421333 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,597 shares Expires 2024-04-08 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 14,597 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 8,906 shares. F1 · derivative.exercise_date: 13,077 of the shares underlying the cancelled option were vested and immediately exercisable. The remaining shares underlying the cancelled option were scheduled to vest monthly in increments of 1/48th of the shares subject to the options. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 16:15 UTC |
Yee James PChief Medical Officer
|
Disposition to issuerOption to Purchase Common Stock · Derivative | 21,897 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026023 · doc4.xml · derivative · entry 1 Yee James P · CIK 0001421336 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,897 shares Expires 2024-04-08 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 21,897 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a stock option for 13,359 shares. F1 · derivative.exercise_date: 19,616 of the shares underlying the cancelled option were vested and immediately exercisable. The remaining shares underlying the cancelled option were scheduled to vest monthly in increments of 1/48th of the shares subject to the options. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:10 UTC |
Cohen Fred EDirector
|
Disposition to issuerOption to Purchase Common Stock · Derivative | 10,948 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026018 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,948 shares Expires 2024-06-19 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F1 · derivative.exercise_date: The shares underlying the cancelled option were vested and immediately exercisable. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:08 UTC |
Goldberg MichaelDirector
|
Disposition to issuerOption to Purchase Common Stock · Derivative | 61,386 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026016 · doc4.xml · derivative · entry 1 Goldberg Michael · CIK 0001366412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,386 shares Expires 2024-04-08 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 61,386 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 37,453 shares. F1 · derivative.exercise_date: 54,992 of the shares underlying the canceled option were vested and immediately exercisable. The remaining shares underlying the cancelled option were scheduled to vest monthly in increments of 1/48th of the shares subject to the options. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:08 UTC |
Maag PeterDirector · See Remarks
|
Disposition to issuerOption to Purchase Common Stock · Derivative | 113,868 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026015 · doc4.xml · derivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,868 shares Expires 2024-04-08 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 113,868 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a stock option for 69,474 shares. F1 · derivative.exercise_date: 102,006 of the shares underlying the cancelled option were vested and immediately exercisable. The remaining shares underlying the cancelled option were scheduled to vest monthly in increments of 1/48th of the shares subject to the options. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:05 UTC |
Bickerstaff GeorgeDirector
|
Disposition to issuerOption to Purchase Common Stock · Derivative | 10,948 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026009 · doc4.xml · derivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,948 shares Expires 2024-06-19 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F1 · derivative.exercise_date: The shares underlying the cancelled option were vested and immediately exercisable. Read SEC document |
| October 27, 2017 Filed Oct 30, 2017 18:00 UTC |
King SashaChief Commercial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-17-024892 · doc4.xml · derivative · entry 1 King Sasha · CIK 0001721150 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-10-27 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on October 20, 2018 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| October 27, 2017 Filed Oct 30, 2017 21:56 UTC |
Maag PeterDirector · See Remarks
|
GrantEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-17-024890 · doc4.xml · derivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-10-27 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on October 20, 2018 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.